India is emerging as a global leader in biosimilars. With the Biopharma SHAKTI initiative and several key biologic patents expiring between 2025–2027, biosimilars research has become one of the most promising and well-funded areas for M.Pharm students in Pharmaceutics, Biotechnology, and Regulatory Affairs.
This guide covers high-impact thesis topics and practical tips for 2026.
Why Biosimilars is One of the Best Choices for M.Pharm in 2026
- Massive market growth with Biopharma SHAKTI funding support
- High demand from companies like Biocon, Dr. Reddy’s, Sun Pharma, Zydus, and Intas
- Excellent scope for publications and international exposure
- Strong alignment with revised PCI syllabus on biologics
- Good transition opportunities to PhD or industry roles in India and abroad
Top M.Pharm Thesis Ideas in Biosimilars Development
-
Formulation and Stability Studies of Trastuzumab Biosimilar
- Focus: Buffer optimization, excipient selection, and aggregation control
-
Analytical Comparability Study of Adalimumab Biosimilar
- Include charge variants, glycan profiling, and bioactivity assays
-
Development of High-Concentration Subcutaneous Monoclonal Antibody Formulation
- Target: 100–200 mg/mL with reduced viscosity
-
Lyophilization Cycle Optimization for Rituximab Biosimilar
- Emphasis on cake appearance, residual moisture, and reconstitution time
-
Site-Specific PEGylation of Filgrastim Biosimilar
- Goal: Improved half-life and reduced immunogenicity
Essential Characterization Techniques for Strong Thesis
- Size Exclusion Chromatography (SEC) with MALS
- Capillary Isoelectric Focusing (CIEF)
- Peptide Mapping and Glycan Analysis
- Cell-based Bioassays for Potency
- Forced Degradation and ICH Stability Studies
Common Challenges & Practical Solutions
- High cost of reference innovator product → Use approved Indian biosimilars as comparator
- Limited advanced analytical facilities → Collaborate with NIPER, CROs or industry partners
- Immunogenicity concerns → Include in-silico and in-vitro assays
- Regulatory complexity → Strictly follow latest CDSCO Biosimilar Guidelines
Future Scope in Biosimilars for 2026–2027
- Push for interchangeable biosimilars with automatic substitution
- Increased government incentives for local manufacturing
- Growth in oncology and autoimmune biosimilars
- Integration of AI/ML for process and similarity assessment
Action Plan to Start Your M.Pharm Thesis
- Select a molecule with upcoming patent expiry
- Review latest CDSCO and ICH guidelines for biosimilars
- Design analytical plan focusing on physicochemical and functional similarity
- Apply Quality by Design (QbD) and DoE approach
- Aim for publication in reputed journals like Biologicals or AAPS PharmSciTech
Biosimilars development offers excellent funding, research output, and career prospects for M.Pharm students in 2026, especially in the Pune-Mumbai biotech corridor.